Note: The job is a remote job and is open to candidates in USA. BayBridge is a clinical-stage oncology biotechnology company developing therapies from first-in-human through late-stage development and registration. The Vice President of Clinical Development will lead clinical development strategy across the oncology portfolio, oversee regulatory interactions and global studies, support business development activities, and build the clinical development team.
Responsibilities
- Own the clinical development strategy across the oncology portfolio, from the IND through Phase 3 and registration
- Lead dose optimisation, indication prioritisation and combination strategy, aligned with FDA's Project Optimus expectations
- Drive the go/no-go decisions at PCC-to-FIH, Phase 2 and Phase 3, backed by data the executive team and board can act on
- Lead FDA interactions, including pre-IND, IND, Type B (end-of-Phase 2 / pre-Phase 3) and pre-NDA/BLA meetings. Author and review briefing packages, the IND and filing dossiers, and agency responses
- Provide medical and safety monitoring oversight across global Phase 1–3 studies
- Build and manage KOL and scientific advisory networks, and bring external input into asset and disease-area strategy
- Partner with BD on due diligence, licensing and co-development partnerships
- Build and mentor a clinical development team as the pipeline matures
Skills
- MD
- 8+ years of industry clinical development experience in oncology, spanning big pharma or biotech
- A track record of taking assets from first-in-human to a Phase 3 go decision, including dose optimisation
- Solid tumour depth
- Experience with targeted small molecules and antibodies, including IO combinations
- Direct FDA meeting experience
- Exposure to BD, partnering and asset licensing
- A publication and congress record (ASCO, ESMO, AACR)
- Ideally NSCLC and/or GI (colorectal)
Benefits
- Hybrid work arrangement in Boston/Cambridge, MA or US remote
Company Overview